Biological and small molecule strategies in migraine therapy with relation to the calcitonin gene-related peptide family of peptides.
CGRP
CLR
RAMPs
adrenomedullin
amylin
calcitonin
receptors
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
10
08
2021
received:
27
03
2021
accepted:
13
08
2021
pubmed:
20
8
2021
medline:
14
4
2022
entrez:
19
8
2021
Statut:
ppublish
Résumé
Migraine is one of the most common of neurological disorders with a global prevalence of up to 15%. One in five migraineurs have frequent episodic or chronic migraine requiring prophylactic treatment. In recent years, specific pharmacological treatments targeting calcitonin gene-related peptide (CGRP) signalling molecules have provided safe and effective treatments, monoclonal antibodies for prophylaxis and gepants for acute therapy. Albeit beneficial, it is important to understand the molecular mechanisms of these new drugs to better understand migraine pathophysiology and improve therapy. Here, we describe current views on the role of the CGRP family of peptides - CGRP, calcitonin, adrenomedullin, amylin - and their receptors in the trigeminovascular system. All these molecules are present within the trigeminovascular system but differ in expression and localization. It is likely that they have different roles, which can be utilized in providing additional drug targets. LINKED ARTICLES: This article is part of a themed issue on Advances in Migraine and Headache Therapy (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.3/issuetoc.
Substances chimiques
Calcitonin Gene-Related Peptide Receptor Antagonists
0
Receptors, Calcitonin Gene-Related Peptide
0
Calcitonin
9007-12-9
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
371-380Informations de copyright
© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 176, S21-S141. https://doi.org/10.1111/bph.14748
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators. (2019a). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors. British Journal of Pharmacology, 176, S247-S296. https://doi.org/10.1111/bph.14751
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators. (2019b). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176, S297-S396. https://doi.org/10.1111/bph.14752
Amara, S. G., Jonas, V., Rosenfeld, M. G., Ong, E. S., & Evans, R. M. (1982). Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature, 298(5871), 240-244. https://www.ncbi.nlm.nih.gov/pubmed/6283379
Amin, F. M., Asghar, M. S., Hougaard, A., Hansen, A. E., Larsen, V. A., de Koning, P. J., Larsson, H. B. W., Olesen, J., & Ashina, M. (2013). Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: A cross-sectional study. Lancet Neurology, 12(5), 454-461. https://doi.org/10.1016/S1474-4422(13)70067-X
Amrutkar, D. V., Ploug, K. B., Hay-Schmidt, A., Porreca, F., Olesen, J., & Jansen-Olesen, I. (2012). mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain, 153(4), 830-838. https://doi.org/10.1016/j.pain.2012.01.005
Ashina, M., Hansen, J. M., Bo, A. D., & Olesen, J. (2017). Human models of migraine-Short-term pain for long-term gain. Nature Reviews. Neurology, 13(12), 713-724. https://doi.org/10.1038/nrneurol.2017.137
Bower, R. L., Eftekhari, S., Waldvogel, H. J., Faull, R. L., Tajti, J., Edvinsson, L., Hay, D. L., & Walker, C. S. (2016). Mapping the calcitonin receptor in human brain stem. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 310(9), R788-R793. https://doi.org/10.1152/ajpregu.00539.2015
Cooper, G. J., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., & Reid, K. B. (1987). Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proceedings of the National Academy of Sciences of the United States of America, 84(23), 8628-8632. https://www.ncbi.nlm.nih.gov/pubmed/3317417
Edvinsson, J. C. A., Warfvinge, K., Krause, D. N., Blixt, F. W., Sheykhzade, M., Edvinsson, L., & Haanes, K. A. (2019). C-fibers may modulate adjacent Adelta-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. The Journal of Headache and Pain, 20(1), 105. https://doi.org/10.1186/s10194-019-1055-3
Edvinsson, L. (2011). Tracing neural connections to pain pathways with relevance to primary headaches. Cephalalgia, 31(6), 737-747. https://doi.org/10.1177/0333102411398152
Edvinsson, L., Alm, R., Shaw, D., Rutledge, R. Z., Koblan, K. S., Longmore, J., & Kane, S. A. (2002). Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. European Journal of Pharmacology, 434(1-2), 49-53. https://www.ncbi.nlm.nih.gov/pubmed/11755165
Edvinsson, L., Chan, K. Y., Eftekhari, S., Nilsson, E., de Vries, R., Saveland, H., Dirven, C. M., Danser, A. J., & MaassenVanDenBrink, A. (2010). Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia, 30(10), 1233-1240. https://doi.org/10.1177/0333102410362122
Edvinsson, L., Ekman, R., Jansen, I., McCulloch, J., & Uddman, R. (1987). Calcitonin gene-related peptide and cerebral blood vessels: Distribution and vasomotor effects. Journal of Cerebral Blood Flow and Metabolism, 7(6), 720-728. https://doi.org/10.1038/jcbfm.1987.126
Edvinsson, L., Fredholm, B. B., Hamel, E., Jansen, I., & Verrecchia, C. (1985). Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neuroscience Letters, 58(2), 213-217. https://www.ncbi.nlm.nih.gov/pubmed/2995876
Edvinsson, L., Goadsby, P. J., & Uddman, R. (2001). Amylin: Localization, effects on cerebral arteries and on local cerebral blood flow in the cat. ScientificWorldJournal, 1, 168-180. https://doi.org/10.1100/tsw.2001.23
Edvinsson, L., Grell, A. S., & Warfvinge, K. (2020). Expression of the CGRP family of neuropeptides and their receptors in the trigeminal ganglion. Journal of Molecular Neuroscience, 70(6), 930-944. https://doi.org/10.1007/s12031-020-01493-z
Edvinsson, L., Haanes, K. A., & Warfvinge, K. (2019). Does inflammation have a role in migraine? Nature Reviews. Neurology, 15(8), 483-490. https://doi.org/10.1038/s41582-019-0216-y
Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018). CGRP as the target of new migraine therapies-Successful translation from bench to clinic. Nature Reviews Neurology, 14(6), 338-350. https://doi.org/10.1038/s41582-018-0003-1
Edvinsson, L., Nilsson, E., & Jansen-Olesen, I. (2007). Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. British Journal of Pharmacology, 150(5), 633-640. https://doi.org/10.1038/sj.bjp.0707134
Eftekhari, S., Gaspar, R. C., Roberts, R., Chen, T. B., Zeng, Z., Villarreal, S., Edvinsson, L., & Salvatore, C. A. (2016). Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography. The Journal of Comparative Neurology, 524(1), 90-118. https://doi.org/10.1002/cne.23828
Eftekhari, S., Salvatore, C. A., Calamari, A., Kane, S. A., Tajti, J., & Edvinsson, L. (2010). Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience, 169(2), 683-696. https://doi.org/10.1016/j.neuroscience.2010.05.016
Eftekhari, S., Salvatore, C. A., Johansson, S., Chen, T. B., Zeng, Z., & Edvinsson, L. (2015). Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Research, 1600, 93-109. https://doi.org/10.1016/j.brainres.2014.11.031
Eftekhari, S., Warfvinge, K., Blixt, F. W., & Edvinsson, L. (2013). Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. The Journal of Pain, 14(11), 1289-1303. https://doi.org/10.1016/j.jpain.2013.03.010
Erdling, A., Sheykhzade, M., & Edvinsson, L. (2017). Differential inhibitory response to telcagepant on αCGRP induced vasorelaxation and intracellular Ca2+ levels in the perfused and non-perfused isolated rat middle cerebral artery. The Journal of Headache and Pain, 18(1), 61. https://doi.org/10.1186/s10194-017-0768-4
Ferrero, H., Larrayoz, I. M., Gil-Bea, F. J., Martinez, A., & Ramirez, M. J. (2018). Adrenomedullin, a novel target for neurodegenerative diseases. Molecular Neurobiology, 55, 8799-8814. https://doi.org/10.1007/s12035-018-1031-y
Ferrero, H., Larrayoz, I. M., Martisova, E., Solas, M., Howlett, D. R., Francis, P. T., Gil-Bea, F. J., Martínez, A., & Ramirez, M. J. (2018). Increased levels of brain adrenomedullin in the neuropathology of Alzheimer's disease. Molecular Neurobiology, 55(6), 5177-5183. https://doi.org/10.1007/s12035-017-0700-6
Findlay, D. M., & Sexton, P. M. (2004). Calcitonin. Growth Factors, 22(4), 217-224. https://doi.org/10.1080/08977190410001728033
Fontaine, D., Almairac, F., Santucci, S., Fernandez, C., Dallel, R., Pallud, J., & Lanteri-Minet, M. (2018). Dural and pial pain-sensitive structures in humans: New inputs from awake craniotomies. Brain, 141(4), 1040-1048. https://doi.org/10.1093/brain/awy005
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the global burden of disease study 2016. Lancet, 390(10100), 1211-1259. https://doi.org/10.1016/s0140-6736(17)32154-2
Ghanizada, H., Al-Karagholi, M. A., Walker, C. S., Arngrim, N., Rees, T., Petersen, J., Siow, A., Mørch-Rasmussen, M., Tan, S., O'Carroll, S. J., & Harris, P. (2021). Amylin analog Pramlintide induces migraine-like attacks in patients. Annals of Neurology, 89, 1157-1171. https://doi.org/10.1002/ana.26072
Ghanizada, H., Al-Mahdi Al-Karagholi, M., Arngrim, N., Morch-Rasmussen, M., Walker, C. S., Hay, D. L., & Ashina, M. (2021). Effect of adrenomedullin on migraine-like attacks in patients with migraine: A randomized crossover study. Neurology, 96, e2488-e2499. https://doi.org/10.1212/WNL.0000000000011930
Gingell, J. J., Hendrikse, E. R., & Hay, D. L. (2019). New insights into the regulation of CGRP-family receptors. Trends in Pharmacological Sciences, 40(1), 71-83. https://doi.org/10.1016/j.tips.2018.11.005
Goadsby, P. J., & Akerman, S. (2012). The trigeminovascular system does not require a peripheral sensory input to be activated-Migraine is a central disorder. Focus on ‘Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system’. Cephalalgia, 32(1), 3-5. https://doi.org/10.1177/0333102411430267
Goadsby, P. J., & Edvinsson, L. (1994). Joint 1994 Wolff award presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache, 34(7), 394-399. https://www.ncbi.nlm.nih.gov/pubmed/7928323, http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.1994.hed3407394.x/abstract
Goadsby, P. J., Edvinsson, L., & Ekman, R. (1988). Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Annals of Neurology, 23(2), 193-196. https://doi.org/10.1002/ana.410230214
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017). Pathophysiology of migraine: A disorder of sensory processing. Physiological Reviews, 97(2), 553-622. https://doi.org/10.1152/physrev.00034.2015
Goadsby, P. J., & Knight, Y. E. (1997). Direct evidence for central sites of action of zolmitriptan (311C90): An autoradiographic study in cat. Cephalalgia, 17(3), 153-158. https://doi.org/10.1046/j.1468-2982.1997.1703153.x
Hadjikhani, N., Albrecht, D. S., Mainero, C., Ichijo, E., Ward, N., Granziera, C., Zürcher, N. R., Akeju, O., Bonnier, G., Price, J., Hooker, J. M., Napadow, V., Nahrendorf, M., Loggia, M. L., & Moskowitz, M. A. (2020). Extra-axial inflammatory signal in parameninges in migraine with visual aura. Annals of Neurology, 87(6), 939-949. https://doi.org/10.1002/ana.25731
Hay, D. L. (2017). Amylin. Headache, 57(Suppl 2), 89-96. https://doi.org/10.1111/head.13077
Hay, D. L., Garelja, M. L., Poyner, D. R., & Walker, C. S. (2018). Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR review 25. British Journal of Pharmacology, 175(1), 3-17. https://doi.org/10.1111/bph.14075
Hay, D. L., Harris, P. W., Kowalczyk, R., Brimble, M. A., Rathbone, D. L., Barwell, J., Conner, A. C., & Poyner, D. R. (2014). Structure-activity relationships of the N-terminus of calcitonin gene-related peptide: Key roles of alanine-5 and threonine-6 in receptor activation. British Journal of Pharmacology, 171(2), 415-426. https://doi.org/10.1111/bph.12464
Hay, D. L., & Pioszak, A. A. (2016). Receptor activity-modifying proteins (RAMPs): New insights and roles. Annual Review of Pharmacology and Toxicology, 56, 469-487. https://doi.org/10.1146/annurev-pharmtox-010715-103120
Hendrikse, E. R., Bower, R. L., Hay, D. L., & Walker, C. S. (2018). Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Cephalalgia, 39, 403-419. https://doi.org/10.1177/0333102418765787
Ho, T. W., Edvinsson, L., & Goadsby, P. J. (2010). CGRP and its receptors provide new insights into migraine pathophysiology. Nature Reviews. Neurology, 6(10), 573-582. https://doi.org/10.1038/nrneurol.2010.127
Hoffmann, J., Wecker, S., Neeb, L., Dirnagl, U., & Reuter, U. (2012). Primary trigeminal afferents are the main source for stimulus-induced CGRP release into jugular vein blood and CSF. Cephalalgia, 32(9), 659-667. https://doi.org/10.1177/0333102412447701
Johnson, K. W., Morin, S. M., Wroblewski, V. J., & Johnson, M. P. (2019). Peripheral and central nervous system distribution of the CGRP neutralizing antibody [(125)I] galcanezumab in male rats. Cephalalgia, 39(10), 1241-1248. https://doi.org/10.1177/0333102419844711
Juhl, L., Petersen, K. A., Larsen, E. H., Jansen-Olesen, I., & Olesen, J. (2006). The in vivo effect of adrenomedullin on rat dural and pial arteries. European Journal of Pharmacology, 538(1-3), 101-107. https://doi.org/10.1016/j.ejphar.2006.03.005
Khan, S., Amin, F. M., Fliedner, F. P., Christensen, C. E., Tolnai, D., Younis, S., Olinger, A. C. R., Birgens, H., Daldrup-Link, H., Kjaer, A., Larsson, H. B. W., Lindberg, U., & Ashina, M. (2019). Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. Cephalalgia, 39(11), 1407-1420. https://doi.org/10.1177/0333102419848122
Kitamura, K., Kangawa, K., Kawamoto, M., Ichiki, Y., Nakamura, S., Matsuo, H., & Eto, T. (1993). Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochemical and Biophysical Research Communications, 192(2), 553-560. https://doi.org/10.1006/bbrc.1993.1451
Labastida-Ramirez, A., Rubio-Beltran, E., Haanes, K. A., Chan, K. Y., Garrelds, I. M., Johnson, K. W., Danser, A. H., Villalón, C. M., & MaassenVanDenBrink, A. (2020). Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain, 161(5), 1092-1099. https://doi.org/10.1097/j.pain.0000000000001801
Lennerz, J. K., Ruhle, V., Ceppa, E. P., Neuhuber, W. L., Bunnett, N. W., Grady, E. F., & Messlinger, K. (2008). Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution. The Journal of Comparative Neurology, 507(3), 1277-1299. https://doi.org/10.1002/cne.21607
Levy, D., Burstein, R., & Strassman, A. M. (2005). Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: Implications for the pathophysiology of migraine. Annals of Neurology, 58(5), 698-705. https://doi.org/10.1002/ana.20619
Lundblad, C., Haanes, K. A., Grande, G., & Edvinsson, L. (2015). Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage. The Journal of Headache and Pain, 16, 91. https://doi.org/10.1186/s10194-015-0575-8
May, A., & Burstein, R. (2019). Hypothalamic regulation of headache and migraine. Cephalalgia, 39, 1710-1719. https://doi.org/10.1177/0333102419867280
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998). RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature, 393(6683), 333-339. https://doi.org/10.1038/30666
Messlinger, K., Balcziak, L. K., & Russo, A. F. (2020). Cross-talk signaling in the trigeminal ganglion: Role of neuropeptides and other mediators. Journal of Neural Transmission, 127(4), 431-444. https://doi.org/10.1007/s00702-020-02161-7
Mietlicki-Baase, E. G., McGrath, L. E., Koch-Laskowski, K., Krawczyk, J., Reiner, D. J., Pham, T., Nguyen, C. T. N., Turner, C. A., Olivos, D. R., Wimmer, M. E., Schmidt, H. D., & Hayes, M. R. (2017). Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior. Neuropharmacology, 123, 67-79. https://doi.org/10.1016/j.neuropharm.2017.05.024
Miller, S., Liu, H., Warfvinge, K., Shi, L., Dovlatyan, M., Xu, C., & Edvinsson, L. (2016). Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies. Neuroscience, 328, 165-183. https://doi.org/10.1016/j.neuroscience.2016.04.046
Mulder, H., Leckstrom, A., Uddman, R., Ekblad, E., Westermark, P., & Sundler, F. (1995). Islet amyloid polypeptide (amylin) is expressed in sensory neurons. The Journal of Neuroscience, 15(11), 7625-7632. https://www.ncbi.nlm.nih.gov/pubmed/7472513
Mulder, I. A., Li, M., de Vries, T., Qin, T., Yanagisawa, T., Sugimoto, K., van den Bogaerdt, A., Danser, A. J., Wermer, M. J., van den Maagdenberg, A. M., & MaassenVanDenBrink, A. (2020). Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Annals of Neurology, 88(4), 771-784. https://doi.org/10.1002/ana.25831
Murinson, B. B., & Griffin, J. W. (2004). C-fiber structure varies with location in peripheral nerve. Journal of Neuropathology & Experimental Neurology, 63(3), 246-254. https://doi.org/10.1093/jnen/63.3.246
Noseda, R., Schain, A. J., Melo-Carrillo, A., Tien, J., Stratton, J., Mai, F., Strassman, A. M., & Burstein, R. (2020). Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Cephalalgia, 40(3), 229-240. https://doi.org/10.1177/0333102419896760
Ohlsson, L., Haanes, K. A., Kronvall, E., Xu, C., Snellman, J., & Edvinsson, L. (2019). Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries. Cephalalgia, 39(14), 1745-1752. https://doi.org/10.1177/0333102419867282
Ohlsson, L., Kronvall, E., Stratton, J., & Edvinsson, L. (2018). Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries. The Journal of Headache and Pain, 19(1), 66. https://doi.org/10.1186/s10194-018-0905-8
Olesen, J., Burstein, R., Ashina, M., & Tfelt-Hansen, P. (2009). Origin of pain in migraine: Evidence for peripheral sensitisation. Lancet Neurology, 8, 679-690. https://doi.org/10.1016/s1474-4422(09)70090-0
Oliver, K. R., Wainwright, A., Edvinsson, L., Pickard, J. D., & Hill, R. G. (2002). Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. Journal of Cerebral Blood Flow and Metabolism, 22(5), 620-629. https://doi.org/10.1097/00004647-200205000-00014
Pan, K. S., Siow, A., Hay, D. L., & Walker, C. S. (2020). Antagonism of CGRP signaling by rimegepant at two receptors. Frontiers in Pharmacology, 11, 1240. https://doi.org/10.3389/fphar.2020.01240
Pietrobon, D., & Moskowitz, M. A. (2013). Pathophysiology of migraine. Annual Review of Physiology, 75, 365-391. https://doi.org/10.1146/annurev-physiol-030212-183717
Poyner, D. R., Sexton, P. M., Marshall, I., Smith, D. M., Quirion, R., Born, W., Muff, R., Fischer, J. A., & Foord, S. M. (2002). International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacological Reviews, 54(2), 233-246. https://www.ncbi.nlm.nih.gov/pubmed/12037140
Rees, T. A., Hay, D. L., & Walker, C. S. (2021). Amylin antibodies frequently display cross-reactivity with CGRP: Characterization of eight amylin antibodies. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 320(5), R697-R703. https://doi.org/10.1152/ajpregu.00338.2020
Roberts, N. L., Mountjoy-Venning, W. C., Anjomshoa, M., Banoub, J. A., Yasin, Y. J., & GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. Lancet, 392(10159), 1789-1858. https://doi.org/10.1016/s0140-6736(18)32279-7
Rubio-Beltran, E., Chan, K. Y., Danser, A. J., MaassenVanDenBrink, A., & Edvinsson, L. (2020). Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Cephalalgia, 40(4), 357-366. https://doi.org/10.1177/0333102419884943
Satoh, F., Takahashi, K., Murakami, O., Totsune, K., Sone, M., Ohneda, M., Sasano, H., & Mouri, T. (1996). Immunocytochemical localization of adrenomedullin-like immunoreactivity in the human hypothalamus and the adrenal gland. Neuroscience Letters, 203(3), 207-210. https://www.ncbi.nlm.nih.gov/pubmed/8742029
Saxena, P. R., & Den Boer, M. O. (1991). Pharmacology of antimigraine drugs. Journal of Neurology, 238(Suppl 1), S28-S35. https://doi.org/10.1007/BF01642903
Schain, A. J., Melo-Carrillo, A., Stratton, J., Strassman, A. M., & Burstein, R. (2019). CSD-induced arterial dilatation and plasma protein extravasation are unaffected by Fremanezumab: Implications for CGRP's role in migraine with aura. The Journal of Neuroscience, 39(30), 6001-6011. https://doi.org/10.1523/JNEUROSCI.0232-19.2019
Schulte, L. H., Mehnert, J., & May, A. (2020). Longitudinal neuroimaging over 30 days: Temporal characteristics of migraine. Annals of Neurology, 87(4), 646-651. https://doi.org/10.1002/ana.25697
Schulte, L. H., Menz, M. M., Haaker, J., & May, A. (2020). The migraineur's brain networks: Continuous resting state fMRI over 30 days. Cephalalgia, 40(14), 1614-1621. https://doi.org/10.1177/0333102420951465
Schultz, N., Byman, E., Fex, M., & Wennstrom, M. (2017). Amylin alters human brain pericyte viability and NG2 expression. Journal of Cerebral Blood Flow and Metabolism, 37(4), 1470-1482. https://doi.org/10.1177/0271678X16657093
Serrano, J., Uttenthal, L. O., Martinez, A., Fernandez, A. P., de Velasco, J. M., Alonso, D., Bentura, M. L., Santacana, M., Gallardo, J. R., Martínez-Murillo, R., & Cuttitta, F. (2000). Distribution of adrenomedullin-like immunoreactivity in the rat central nervous system by light and electron microscopy. Brain Research, 853(2), 245-268. https://www.ncbi.nlm.nih.gov/pubmed/10640622
Shi, L., Lehto, S. G., Zhu, D. X., Sun, H., Zhang, J., Smith, B. P., Immke, D. C., Wild, K. D., & Xu, C. (2016). Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. The Journal of Pharmacology and Experimental Therapeutics, 356(1), 223-231. https://doi.org/10.1124/jpet.115.227793
Tajti, J., Kuris, A., Vecsei, L., Xu, C. B., & Edvinsson, L. (2011). Organ culture of the trigeminal ganglion induces enhanced expression of calcitonin gene-related peptide via activation of extracellular signal-regulated protein kinase 1/2. Cephalalgia, 31(1), 95-105. https://doi.org/10.1177/0333102410382796
Walker, C. S., Eftekhari, S., Bower, R. L., Wilderman, A., Insel, P. A., Edvinsson, L., Waldvogel, H. J., Jamaluddin, M. A., Russo, A. F., & Hay, D. L. (2015). A second trigeminal CGRP receptor: Function and expression of the AMY1 receptor. Annals of Clinical Translational Neurology, 2(6), 595-608. https://doi.org/10.1002/acn3.197